Keystone Investors PTE Ltd. Takes $3.84 Million Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Keystone Investors PTE Ltd. purchased a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the 4th quarter, Holdings Channel reports. The fund purchased 57,900 shares of the biotechnology company’s stock, valued at approximately $3,844,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ARWR. Tsfg LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at about $25,000. iSAM Funds UK Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at about $29,000. First Horizon Corp purchased a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at about $32,000. WPG Advisers LLC increased its position in shares of Arrowhead Pharmaceuticals by 384.8% during the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 431 shares during the last quarter. Finally, Hantz Financial Services Inc. increased its position in shares of Arrowhead Pharmaceuticals by 177.1% during the 4th quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 471 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Insider Activity at Arrowhead Pharmaceuticals

In related news, Director Hongbo Lu sold 2,970 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total transaction of $228,333.60. Following the completion of the transaction, the director directly owned 52,012 shares in the company, valued at approximately $3,998,682.56. The trade was a 5.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James C. Hamilton sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total value of $750,000.00. Following the transaction, the insider owned 226,958 shares of the company’s stock, valued at approximately $17,021,850. This trade represents a 4.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 26,065 shares of company stock worth $1,912,662. 3.60% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Trading Up 0.1%

Shares of NASDAQ:ARWR opened at $74.52 on Friday. The stock has a 50 day moving average of $72.46 and a 200 day moving average of $66.71. The company has a market cap of $10.50 billion, a PE ratio of -34.66 and a beta of 1.28. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 1.41. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $14.30 and a 12-month high of $82.26.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.17. The company had revenue of $73.74 million during the quarter, compared to the consensus estimate of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The firm’s revenue was down 86.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.75 EPS. As a group, equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3 EPS for the current year.

Analysts Set New Price Targets

ARWR has been the subject of several research reports. Weiss Ratings lowered shares of Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Wednesday, May 20th. Morgan Stanley raised shares of Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $78.00 to $100.00 in a research report on Tuesday, April 21st. Wall Street Zen lowered shares of Arrowhead Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Sanford C. Bernstein upped their price target on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Finally, Royal Bank Of Canada upped their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $87.80.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.